Peptil H 50 mg/2 ml (IM/IV Injection)
Medicine Details
| Category | Details |
|---|---|
| Generic | Ranitidine hydrochloride |
| Company | Eskayef pharmaceuticals ltd |
| Also available as |
Indications
- Treatment of active duodenal ulcer
- Benign gastric ulcer
- Treatment & prevention of ulcer associated with non-steroidal anti-inflammatory agent
- Post-operative stress ulcer
- Zollinger-Ellison Syndrome
- Gastroesophageal reflux disease (GERD)
- Gastrointestinal haemorrhage from stress ulcer in seriously ill patient
- Recurrent haemorrhage in patients with bleeding peptic ulcer
- Before general anesthesia in patient considered to be at risk of acid aspiration particularly obstetric patients
Pharmacology
Ranitidine competitively blocks histamine at H2-receptors of the gastric parietal cells, inhibiting gastric acid secretion. It does not affect pepsin secretion, pentagastrin-stimulated intrinsic factor secretion, or serum gastrin.
Dosage & Administration
- Usual dosage for duodenal and gastric ulcer is 150 mg twice daily for 4 to 8 weeks
- For reflux oesophagitis, the dosage is 150 mg twice daily or 300 mg at bedtime for up to 8 weeks
- For Zollinger Ellison syndrome, the dosage is 150 mg 3 times daily and may be increased if necessary up to 6 g daily in divided doses
- Episodic dyspepsia: 150 mg twice daily or 300 mg at bedtime for up to 6 weeks
- Maintenance: 150 mg at night for preventing recurrences
- For children with peptic ulcer, the dosage is 2-4 mg/kg twice daily, maximum 300 mg daily
Interaction
Delayed absorption and increased peak serum concentration with propantheline bromide. Peptil H minimally inhibits hepatic metabolism of coumarin anticoagulants, theophylline, diazepam, and propanolol. May alter absorption of pH-dependent drugs (e.g. ketoconazole, midazolam, glipizide). May reduce bioavailability with antacids.
Contraindications
Patients hypersensitive to Ranitidine
Side Effects
- Altered bowel habit
- Dizziness
- Rash
- Tiredness
- Reversible confusional states
- Headache
- Decreased blood counts
- Muscle or joint pain
Pregnancy & Lactation
- Ranitidine crosses the placenta
- No evidence of impaired fertility or harm to the fetus due to Ranitidine
- Caution should be exercised when the drug is administered to a nursing mother
Precautions & Warnings
Peptil H should be given in reduced dosage to patients with impaired renal and hepatic function
Use in Special Populations
Ulcer healing rates have been found similar in elderly patients
Overdose Effects
No particular problems are expected following overdosage with the drug. Symptomatic and supportive therapy should be given as appropriate. If required, the drug may be removed from the plasma by haemodialysis.
Therapeutic Class
H2 receptor antagonist
Reconstitution
- Peptil H 50 mg diluted to a concentration ≤2.5 mg/mL with NaCl 0.9% injection or dextrose 5% or 10%, lactated Ringer's, Na bicarbonate 5% solution
- Peptil H 50 mg diluted to a concentration ≤0.5 mg/mL of dextrose 5% injection or NaCl 0.9%, lactated Ringer's, Na bicarbonate 5% solution for intermittent slow IV infusion
- Peptil H 150 mg diluted in 250 mL of dextrose 5% injection or NaCl 0.9%, lactated Ringer's, Na bicarbonate 5% solution for continuous IV infusion
Storage Conditions
Store in a cool and dry place, protect from light